Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study -

Additional follow-up of the IMspire150 trial showed that overall survival was not significantly improved with atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and

1597893196998053889

The Lancet Oncology

Online first: Overall #survival with first-line #atezolizumab in combination with #vemurafenib+#cobimetinib in BRAFV600 mutation-positive advanced #melanoma: second interim analysis of IMspire150 https://t.co/8D8ccSYz8B - view on twitter

More coverage: #atezolizumab #cobimetinib #Melanoma #survival #Vemurafenib

Read the full article here

See more from The Lancet Oncology